What's Happening?
After more than a decade of global consultation, polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS). This change, announced at the European Congress of Endocrinology, aims to better reflect the condition's
complex nature, which affects not only reproductive health but also metabolism and cardiovascular risk. The renaming effort was led by endocrinologist Prof. Helena Teede and involved collaboration with international societies and patient groups. The new name addresses the misleading focus on ovarian cysts and highlights the broader hormonal and metabolic implications of the condition.
Why It's Important?
The renaming of PCOS to PMOS is a significant step in improving the understanding and treatment of a condition that affects one in eight women. By shifting the focus from ovarian cysts to the broader hormonal and metabolic aspects, the new name aims to reduce confusion and improve patient care. This change is expected to lead to earlier diagnoses and more comprehensive treatment strategies, addressing not only reproductive health but also associated risks such as diabetes and cardiovascular disease.
What's Next?
The new name will be incorporated into international guidelines for managing the condition, with full implementation expected by 2028. This transition will involve educating healthcare providers and patients about the broader implications of PMOS and the importance of addressing its metabolic and hormonal dimensions. The initiative is part of a larger effort to improve awareness and treatment of the condition, with ongoing research into its causes and management strategies.
